{"id":161127,"date":"2026-09-07T12:01:12","date_gmt":"2026-09-07T12:01:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/161127\/"},"modified":"2026-09-07T12:01:12","modified_gmt":"2026-09-07T12:01:12","slug":"novo-nordisks-ziltivekimab-stumbles-again-on-pair-of-phase-iii-terminations-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/161127\/","title":{"rendered":"Novo Nordisk\u2019s ziltivekimab stumbles again on pair of Phase III terminations"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo Nordisk has opted to prematurely end two Phase III trials of its inflammation-targeting candidate, ziltivekimab, after the drug was deemed unlikely to meet its goals in either study.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">In a statement to Clinical Trials Arena, Novo Nordisk noted that it informed investigators on 4 September that both the HERMES (NCT05636176) and ATHENA (NCT06200207) trials evaluating the IL-6-targeting therapy would end early. Both studies were pitting ziltivekimab against placebo in patients with heart failure and inflammation. The news was first reported by Endpoints on 7 September.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">According to the Danish pharma giant, it made this call based on a recommendation from the data monitoring committee who, after reviewing the totality of the data, concluded that it was unlikely for both the HERMES and ATHENA trials to reach a different outcome to the Phase III ZEUS trial, which missed its primary endpoint in July.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo designed HERMES to evaluate ziltivekimab&#8217;s impact on the time to first occurrence of heart failure endpoints \u2013 including cardiovascular death and heart failure-linked hospitalisations or urgent visits, while ATHENA looked at the drug&#8217;s potential to influence a wide variety of heart failure-specific factors such as quality of life.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The ZEUS study (NCT05021835) marked a notable setback for ziltivekimab&#8217;s late-stage development programme after the drug failed to reduce the risk of major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation.<\/p>\n<p>Novo to pin hopes on the ARTEMIS trial<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">While the outcomes of the ZEUS, HERMES and ATHENA will be disappointing for Novo, the company still has an opportunity for success with ziltivekimab, as a spokesperson told Clinical Trials Arena it will continue the Phase III ARTEMIS trial as planned. This study is currently evaluating the drug&#8217;s potential as an acute treatment in the post-heart attack setting, with a data readout expected in the first half of 2027.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">As for the HERMES and ATHENA studies, Novo added: &#8220;All patients will be followed through to their three-months follow-up visit as already planned.&#8221;<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo originally gained the rights to ziltivekimab, a once-monthly subcutaneous injectable, through its <a data-ylk=\"slk:$725m upfront takeover;elm:context_link;itc:0;sec:content-canvas;\" data-yga=\"{&quot;yLinkElement&quot;:&quot;link&quot;,&quot;yLinkElementType&quot;:&quot;article_link&quot;}\" href=\"https:\/\/www.pharmaceutical-technology.com\/features\/novo-nordisk-corvidia-deal\/\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">$725m upfront takeover<\/a> of Massachusetts-based biotech, Corvidia Therapeutics, back in 2020.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">&#8220;Novo Nordisk&#8217;s ziltivekimab stumbles again on pair of Phase III terminations&#8221; was originally created and published by <a data-ylk=\"slk:Clinical Trials Arena;elm:context_link;itc:0;sec:content-canvas;\" data-yga=\"{&quot;yLinkElement&quot;:&quot;link&quot;,&quot;yLinkElementType&quot;:&quot;article_link&quot;}\" href=\"https:\/\/www.clinicaltrialsarena.com\/news\/novo-nordisk-ziltivekimab-phase-iii-terminations\/\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">Clinical Trials Arena<\/a>, a GlobalData owned brand.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk has opted to prematurely end two Phase III trials of its inflammation-targeting candidate, ziltivekimab, after the&hellip;\n","protected":false},"author":2,"featured_media":161128,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[18613,75580,30673,3845,272],"class_list":["post-161127","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-athena","tag-clinical-trials-arena","tag-hermes","tag-novo","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117229655525809564","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=161127"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161127\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/161128"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=161127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=161127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=161127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}